Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...

In AL amyloidosis, abnormal plasma cells in the bone marrow produce misfolded proteins that clump together clump together ...

The cereblon E3 ligase modulator, given in combination with Amgen's Kyprolis (carfilzomib) and dexamethasone (Kd) as ...

Eli Lilly's Verzenio could offer the first targeted therapy for dedifferentiated liposarcoma (DDLPS), an aggressive cancer that usually needs to be treated with chemotherapy, according to the results ...

Eli Lilly's relentless pipeline-building drive has continued with a licensing agreement for sonefpeglutide, a GLP-2 analogue developed by Hanmi Pharma, across multiple gastrointestinal indications.

Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows ...

At this year’s ASCO Annual Meeting, Pfizer had three major Phase 3 oral presentations: CROWN, TALAPRO-3, and BREAKWATER, each paired with simultaneous publications in leading medical journals.

Revolution Medicines' pan-RAS (on) inhibitor daraxonrasib has delivered a big result in pancreatic cancer, with a doubling in overall survival compared to chemotherapy in the highly anticipated ...

The FDA has started a priority review of Sanofi's Gaucher disease therapy venglustat, a potentially first-in-class therapy, ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Sudden unexpected death is a terrifying consequence faced by people living with uncontrolled tonic-clonic seizures (TCSs), so ...

Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that ...